PDI, Inc. (NASDAQ: PDII) reported Q3 EPS of ($0.31), $0.09 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $36.6 million versus the consensus estimate of $32.35 million.

"We believe that our recently announced plan to focus our energy and resources entirely on our expanding molecular diagnostics business, along with the implementation of numerous cost efficiencies will build long term value for our shareholders. With our improved balance sheet following the close of the deal, we plan to be able to further develop our commercial capabilities as well as bring new products to market, namely BarreGen for Barrett's Esophagus, which we plan to launch in 2016," commented Nancy Lurker, President and Chief Executive Officer of PDI.

For earnings history and earnings-related data on PDI, Inc. (PDII) click here.